CD4 and neoplasm: Concurrently, this study validated the high expression of CLDN18.2 in a large clinical cohort, emphasizing its crucial value in early tumor prognosis assessment and its interaction with immune‐related molecules, such as PD‐L1, CD3, and CD4.